These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 2369816)

  • 21. Prevalence and mechanisms of aminoglycoside resistance. A ten-year study.
    Phillips I; King A; Shannon K
    Am J Med; 1986 Jun; 80(6B):48-55. PubMed ID: 3728534
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antimicrobial susceptibilities of blood culture isolates obtained before and after the introduction of ciprofloxacin.
    Pieroni P; Goodfellow J; Reesor L; Louie M; Simor AE
    J Antimicrob Chemother; 1997 Mar; 39(3):419-22. PubMed ID: 9096194
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phenotypic resistance of Staphylococcus aureus, selected Enterobacteriaceae, and Pseudomonas aeruginosa after single and multiple in vitro exposures to ciprofloxacin, levofloxacin, and trovafloxacin.
    Gilbert DN; Kohlhepp SJ; Slama KA; Grunkemeier G; Lewis G; Dworkin RJ; Slaughter SE; Leggett JE
    Antimicrob Agents Chemother; 2001 Mar; 45(3):883-92. PubMed ID: 11181375
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparative in vitro activity of the new difluoro-quinolone temafloxacin (A-62254) against bacterial isolates from cancer patients.
    Rolston KV; Ho DH; LeBlanc B; Gooch G; Bodey GP
    Eur J Clin Microbiol Infect Dis; 1988 Oct; 7(5):684-6. PubMed ID: 3143585
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [In vitro antibacterial activity of a new oral cephalosporin, ceftibuten. Results of a multicenter study].
    Soussy CJ; Meyran M; Chanal M; Reverdy ME; Kitzis MD; Derlot E
    Pathol Biol (Paris); 1991 May; 39(5):396-402. PubMed ID: 1909017
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Post-marketing surveillance of antibacterial activities of cefozopran against various clinical isolates--II. Gram-negative bacteria].
    Igari J; Oguri T; Hiramatsu N; Akiyama K; Koyama T
    Jpn J Antibiot; 2002 Feb; 55(1):22-60. PubMed ID: 11977920
    [TBL] [Abstract][Full Text] [Related]  

  • 27. In vitro activity of ciprofloxacin against gram-positive bacteria. An overview.
    Kayser FH; Novak J
    Am J Med; 1987 Apr; 82(4A):33-9. PubMed ID: 3555058
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Susceptibility of common pathogenic bacteria to seven tetracycline antibiotics in vitro.
    Steigbigel NH; Reed CW; Finland M
    Am J Med Sci; 1968 Mar; 255():179-95. PubMed ID: 4384524
    [No Abstract]   [Full Text] [Related]  

  • 29. Ciprofloxacin disk susceptibility tests: interpretive zone size standards for 5-microgram disks.
    Barry AL; Fass RJ; Anhalt JP; Neu HC; Thornsberry C; Tilton RC; Painter BG; Washington JA
    J Clin Microbiol; 1985 Jun; 21(6):880-3. PubMed ID: 3159749
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antibacterial properties of imipenem with special reference to the activity against methicillin-resistant staphylococci, cefotaxime-resistant Enterobacteriaceae and Pseudomonas aeruginosa.
    Vurma-Rapp U; Kayser FH; Barberis-Maino L
    J Antimicrob Chemother; 1986 Dec; 18 Suppl E():27-33. PubMed ID: 3102452
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In-vitro activity of enoxacin against aminoglycoside-resistant gram-negative bacilli and other clinical isolates.
    Duncan IB; Skulnick M; Marshall PW
    J Antimicrob Chemother; 1984 Sep; 14 Suppl C():1-6. PubMed ID: 6438046
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Antibacterial activity in vitro and beta-lactamase stability of the new cephalosporin HR 810 in comparison with five other cephalosporins and two aminoglycosides.
    Seibert G; Limbert M; Winkler I; Dick T
    Infection; 1983; 11(5):275-9. PubMed ID: 6315595
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [In vitro antibacterial activity of a new fluoroquinolone, temafloxacin, against hospital isolates. Results of a multicenter study].
    Soussy CJ; Morel C; Kitzis MD; Meyran M; Brun Y; Joly-Guillou ML; Dabernat H; Chanal M; Courtieu AL; Derlot E
    Pathol Biol (Paris); 1991 May; 39(5):403-9. PubMed ID: 1881670
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of the in vitro activities of BB-K8 and three other aminoglycosides against 215 strains of Pseudomonas and Enterobacteriaceae with variable sensitivity to kanamycin and gentamicin.
    Yourassowsky E; Schoutens E; Vanderlinden MP
    Chemotherapy; 1975; 21(1):45-51. PubMed ID: 807457
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antimicrobial susceptibility of the pathogens of bacteraemia in the UK and Ireland 2001-2002: the BSAC Bacteraemia Resistance Surveillance Programme.
    Reynolds R; Potz N; Colman M; Williams A; Livermore D; MacGowan A;
    J Antimicrob Chemother; 2004 Jun; 53(6):1018-32. PubMed ID: 15128723
    [TBL] [Abstract][Full Text] [Related]  

  • 36. In vitro susceptibility of gentamicin and/or tobramycin resistant gram-negative bacilli to seven aminoglycosides.
    Watanakunakorn C; Kauffman CA
    Infection; 1978; 6(3):111-5. PubMed ID: 98451
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Molecular epidemiology of endemic ciprofloxacin-susceptible and -resistant Enterobacteriaceae.
    Yee YC; Muder RR; Hsieh MH; Lee TC
    Infect Control Hosp Epidemiol; 1992 Dec; 13(12):706-10. PubMed ID: 1337751
    [TBL] [Abstract][Full Text] [Related]  

  • 38. In-vitro susceptibility of 1982 respiratory tract pathogens and 1921 urinary tract pathogens against 19 antimicrobial agents: a Canadian multicentre study. Canadian Antimicrobial Study Group.
    Blondeau JM; Yaschuk Y; Suter M; Vaughan D
    J Antimicrob Chemother; 1999 Mar; 43 Suppl A():3-23. PubMed ID: 10225567
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In vitro evaluation of Ro 23-6240, a new fluorinated 4-quinolone.
    Stobberingh EE; Houben AW; van Boven CP
    Chemotherapy; 1987; 33(3):197-203. PubMed ID: 3109817
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In vitro activity of SCH-34343, a new penam, and other antimicrobial agents against clinical isolates from cancer patients.
    Rolston KV; Alvarez ME; Hoy JF; Alderman HC; Ho DH; Bodey GP
    Chemotherapy; 1986; 32(6):506-14. PubMed ID: 3100147
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.